如何从源头降低我国肝细胞癌发病率  

How to reduce the incidence of hepatocellular carcinoma from the source in China

作　　者：刘建军 刘建国 刘常林 陈志平 牛蓓[2] Liu Jianjun;Liu Jianguo;Liu Changlin;Chen Zhiping;Niu Bei(The Hepatology Research Institute of Handan,Handan 056017,China)

机构地区：[1]河北省邯郸市肝病研究所,邯郸056017 [2]河北省疾病预防控制中心,石家庄050001

出　　处：《新医学》2020年第4期250-253,共4页Journal of New Medicine

摘　　要：肝细胞癌(HCC)已占全球癌症死亡的第3位,其中半数以上病例在中国.目前我国HCC发病率仍无下降趋势,如何从源头降低HCC发病率至关重要.该文重点讨论了肝功能正常HBV携带者抗病毒治疗及他汀类药物干预非酒精性脂肪性肝病、酒精性肝病是否可以从源头降低相关HCC发病率等问题,并根据理论依据及临床观察资料提出可行性报告,旨在从源头降低HCC发病率.Hepatocellular carcinoma(HCC)is the third leading cause of cancer death worldwide,and more than half of the patients are from China.At present,the incidence of HCC in China is still not declining.How to reduce the incidence of HCC from the source is of significance.In this article,whether antiviral therapy for hepatitis B virus(HBV)carriers with normal liver function and statins intervention in nonalcoholic fatty liver disease and alcoholic liver disease could reduce the incidence of related HCC from the source was investigated.According to the theoretical basis and clinical observational data,the feasibility report was proposed to discuss how to lower the incidence of HCC from the source in China.

关 键 词：乙型肝炎病毒携带者 抗病毒治疗 非酒精性脂肪性肝病 酒精性肝病 肝细胞癌 

分 类 号：R735.7[医药卫生—肿瘤]